286 related articles for article (PubMed ID: 28785760)
1. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
2. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
3. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Joseph JS; Lam V; Patel MI
Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
[TBL] [Abstract][Full Text] [Related]
5. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
[TBL] [Abstract][Full Text] [Related]
6. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
11. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation-associated bone disease.
Skolarus TA; Caram MV; Shahinian VB
Curr Opin Urol; 2014 Nov; 24(6):601-7. PubMed ID: 25144145
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
14. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
16. Management of osteoporosis in men on androgen deprivation therapy.
Adler RA
Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP
Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126
[TBL] [Abstract][Full Text] [Related]
18. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
